Oct-10 -

Head & Neck Group

EORTC 24971 – A randomized phase III multicenter trial of neoadjuvant docetaxel (Taxotere) plus cisplatin plus 5-fluorouracil versus neoadjuvant cisplatin plus 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck.

EORTC compared two treatment regimens in patients with inoperable locoregionally advanced squamous cell carcinoma of the head and neck. It found that induction therapy by three chemotherapy drugs rather than two, followed by radiotherapy improved survival, reduced toxicity in patients and improved the overall health-related quality of life (HRQOL) of these patients.

READ MORE

Go to Top